Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Negative Impact 4 of 5 legal/regulatory Written later

PharmaCyte Biotech received a Nasdaq notice on December 1, 2025, saying its common stock no longer meets the $1.00 minimum bid price for continued listing on the Nasdaq Capital Market. The notice has no immediate effect on listing or trading, and the company has until June 1, 2026 to regain compliance, which matters to shareholders because continued failure could lead to delisting.

Key points

  • Nasdaq notice dated December 1, 2025 cites failure to meet the $1.00 minimum bid price under Listing Rule 5550(a)(2)
  • Compliance Date is June 1, 2026, a 180-day period; regaining compliance requires at least $1.00 closing bid for 10 consecutive business days
  • Stock continues to trade under PMCB; the company may seek a second 180-day period or consider a reverse stock split subject to stockholder approval

The filing

CompanyPharmaCyte Biotech, Inc. (PMCB)
Form8-K, current report
Filed with the SECDec 5, 2025, 5:00 PM ET
Accession number0001683168-25-008947

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.